Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 392-397

  Gridelli, C ^a   Perrone, F ^a   Gallo, C ^h   De Marinis, F ^b   Ianniello, G ^c   Cigolari, S ^d   Cariello, S ^e   Di Costanzo, F ^f   D'Aprile, M ^g   Rossi, A ^a   Migliorino, R ^c   Bartolucci, R ^h   Bianco, A R ^d   Pergola, M ^a   Monfardini, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c G RUMMO HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Ospedale S Leonardo   (Italy)

^f S MARIA HOSPITAL   (Italy)

^g SANTA MARIA GORETTI HOSPITAL   (Italy)

^h Ospedale S Maria Goretti ^*

Author keywords

elderly; non small cell lung cancer; vinorelbine

Indexed keywords

NAVELBINE;

ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031105526     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89011-9     Document Type: Article

References (27)

1. Silverberg E. Cancer statistics. CA J. 38:1988;5-22.
2. Cormier Y, Bergeron D, La Farge J, et al. Benefits of polichemotherapy in advanced non small cell bronchogenic carcinoma. Cancer. 50:1992;845-849.
3. Rapp E, Peter J, Villan A, et al. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer. Report of a Canadian multicenter randomized trial. J Clin Oncol. 6:1988;633-641.
4. Cartei G, Cartei F, Cantone A, et al. Cisplatin, cyclophosphamide mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non small cell lung cancer. J Natl Cancer Inst. 85:1993;794-800.
5. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 311:1995;899-909.
6. Furuse K, Kubota K, Korwahara M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non small cell lung cancer. Lung Cancer. 11:1994;385-391.
7. Le Chevalier T, Brisgand D, Dovillard J, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non small cell lung cancer: a result of a European Multicenter Trial including 612 patients. J Clin Oncol. 12:1994;360-367.
8. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 5:1994;37-42.
9. Colleoni M, Geion F, Nelli P, et al. Weekly vinorelbine in elderly patients with non small cell lung cancer. Tumori. 80:1994;448-452.
10. Simon R. Optimal two-stage designs for phase II clinical trials. Contr Clin Trials. 10:1989;1-10.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
12. Hollen PJ, Gralla RJ, Kris M, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer. 29A:(Suppl. 1):1993;S51-S58.
13. Lentner C. 8th edn. Geigy Scientific Tables. 1982.
14. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
15. Dixon WJ. BMDP Statistical Software. 1992;University of California Press, Los Angeles, CA.
16. Salvati F, Antilli A, Cruciani AR, et al. Lonidamine plus cyclophosphamide in the treatment of advanced non small cell lung cancer in the elderly: a phase II study. Tumori. 81:1995;48-51.
17. Rosti G, Zumaglini F, Gridelli C, et al. Carboplatin and oral VP-16 in advanced lung cancer patients aged ≥70 years. A phase II trial. Cancer in the Elderly. Genova. 19-21 September, 1994.
18. Thomas P, Castelnau O, Kleisbauer JP. Carboplatin plus oral etoposide in elderly patients with bronchogenic carcinoma. A phase II trial. Cancer in the Elderly. 19-21 September, 1994;. Genova.
19. Malarme M, Marcelis L, Kalas JP, et al. Ifosfamide (IFO) and vindesine (VDS) therapy for non small cell lung cancer (NSCLC) in the elderly. Ann Oncol. 3:(Suppl. 5):1992;36.
20. Gallotti P, Chiesa E, Olgiati A, et al. Vindesine as monochemotherapy in non small cell lung cancer (NSCLC) in elderly patients. Ann Oncol. 3:(Suppl. 5):1992;36.
21. Portalone L, D'Aprile M, De Marinis F, et al. Management of chemotherapy in elderly patients with advanced non small lung cancer (NSCLC): a phase III randomized trial. Lung Cancer. 11:(Suppl. 1):1994;110.
22. Baldini E, Tibaldi E, Pfanner E, et al. Phase II study of oral doxifluridine in elderly patients with advanced non small cell lung cancer. Am J Clin Oncol. 19:1996;592-594.
23. Rosso R, Martin C. Effect of patient age on gemcitabine toxicity profile and efficacy in advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 13:1994;366. (abstract).
24. Zaheer W, Lichtman SM, De Marco L, et al. The use of taxol in elderly patients. Proc Am Soc Clin Oncol. 13:1994;441. (abstract).
25. Crivellari D, Veronesi A, Sacco C, et al. Phase II study of vinorelbine (v) in 50 patients (pts) with non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 13:1994;355. (abstract).
26. Colleoni M, Vicario G, Pancheri F, et al. Weekly carboplatin and vinorelbine in elderly patients with non small cell lung cancer (NSCLC). VI International Congress on Anti-Cancer Treatment. 6-9 February, 1996.
27. Gridelli C, Perrone F, Palmeri S, et al. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non small cell lung cancer: a phase III multicentre randomised trial. Ann Oncol. 7:1996;821-826.